Ensuring best practice in the notifications of product discontinuation: Best practice guidelines
Discontinuing a medicine is a decision that most pharmaceutical companies will take at some point.
The Department of Health and the ABPI want to ensure that the impact of such a decision on patients is minimised and therefore we have worked together – and with industry representatives and healthcare professionals – to produce these good practice guidelines.
Last modified: 20 September 2023
Last reviewed: 20 September 2023